Phathom Pharmaceuticals Inc

Phathom insider transaction: Parikh Asit sells 40,000 shares but immediately places them in a spouse‑benefit trust, indicating a wealth‑management move that’s neutral for the stock while investors keep an eye on its oncology pipeline.

Insightful look at Phathom Pharma’s insider trades: Breedlove’s 11% stake boost amid price swings, highlighting executive confidence and future upside potential.

Phathom Pharmaceuticals insider buy: 8,750 shares at $10.30—below $15.14—signals long‑term confidence in GI therapeutics and a potential value play amid low P/E, regulatory hurdles.